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High-throughput mutation profiling of CTCL samples reveals
KRAS and NRAS mutations sensitizing tumors toward inhibition
of the RAS/RAF/MEK signaling cascade
Abstract
Cutaneous T-cell lymphomas (CTCLs) are malignancies of skin-homing lymphoid cells, which have so
far not been investigated thoroughly for common oncogenic mutations. We screened 90 biopsy
specimens from CTCL patients (41 mycosis fungoides, 36 Sézary syndrome, and 13 non-mycosis
fungoides/Sézary syndrome CTCL) for somatic mutations using OncoMap technology. We detected
oncogenic mutations for the RAS pathway in 4 of 90 samples. One mycosis fungoides and one
pleomorphic CTCL harbored a KRAS(G13D) mutation; one Sézary syndrome and one CD30(+) CTCL
harbored a NRAS(Q61K) amino acid change. All mutations were found in stage IV patients (4 of 42)
who showed significantly decreased overall survival compared with stage IV patients without mutations
(P = .04). In addition, we detected a NRAS(Q61K) mutation in the CTCL cell line Hut78. Knockdown
of NRAS by siRNA induced apoptosis in mutant Hut78 cells but not in CTCL cell lines lacking RAS
mutations. The NRAS(Q61K) mutation sensitized Hut78 cells toward growth inhibition by the MEK
inhibitors U0126, AZD6244, and PD0325901. Furthermore, we found that MEK inhibitors exclusively
induce apoptosis in Hut78 cells. Taken together, we conclude that RAS mutations are rare events at a
late stage of CTCL, and our preclinical results suggest that such late-stage patients profit from MEK
inhibitors.
doi:10.1182/blood-2010-09-305128
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LYMPHOID NEOPLASIA
High-throughput mutation profiling of CTCL samples reveals KRAS and
NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK
signaling cascade
*Michael K. Kießling,1 *Patrick A. Oberholzer,2-5 Chandrani Mondal,3,4 Maria B. Karpova,5 Marie C. Zipser,5 William M. Lin,6
Michael Girardi,6 Laura E. MacConaill,2-4 Sarah M. Kehoe,3,4 Charlie Hatton,2-4 Lars E. French,5 Levi A. Garraway,2-4
Gernot Polier,1 Dorothee Su¨ss,1 Claus-Detlev Klemke,7 Peter H. Krammer,1 †Karsten Gu¨low,1 and †Reinhard Dummer5
1German Cancer Research Center, Heidelberg, Germany; 2Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA; 3Department
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Cutaneous T-cell lymphomas (CTCLs) are
malignancies of skin-homing lymphoid
cells, which have so far not been investi-
gated thoroughly for common oncogenic
mutations. We screened 90 biopsy speci-
mens from CTCL patients (41 mycosis
fungoides, 36 Se´zary syndrome, and
13 non–mycosis fungoides/Se´zary syn-
drome CTCL) for somatic mutations us-
ing OncoMap technology. We detected
oncogenic mutations for the RAS path-
way in 4 of 90 samples. One mycosis
fungoides and one pleomorphic CTCL
harbored a KRASG13D mutation; one Se´z-
ary syndrome and one CD30 CTCL har-
bored a NRASQ61K amino acid change. All
mutations were found in stage IV patients
(4 of 42) who showed significantly de-
creased overall survival compared with
stage IV patients without mutations
(P  .04). In addition, we detected a
NRASQ61K mutation in the CTCL cell line
Hut78. Knockdown of NRAS by siRNA
induced apoptosis in mutant Hut78 cells
but not in CTCL cell lines lacking RAS
mutations. The NRASQ61K mutation sensi-
tized Hut78 cells toward growth inhibition
by the MEK inhibitors U0126, AZD6244,
and PD0325901. Furthermore, we found
that MEK inhibitors exclusively induce
apoptosis in Hut78 cells. Taken together,
we conclude that RAS mutations are rare
events at a late stage of CTCL, and our
preclinical results suggest that such late-
stage patients profit from MEK inhibitors.
(Blood. 2011;117(8):2433-2440)
Introduction
Cutaneous T-cell lymphomas (CTCLs) are rare malignancies of
skin-homing T lymphocytes. Curative modalities have thus far
proven elusive. CTCL microarray studies have revealed natural
clusters in association with prognosis.1 Array-based comparative
genomic hybridization (CGH) combined with gene expression
profiling identified highly recurrent chromosomal alterations both
in mycosis fungoides (MF) and Se´zary syndrome (SS) patient
specimens.2,3 For example, FASTK and SKAP1 gene loci showed
recurrent gains, and these genes also exhibited increased expres-
sion, whereas RB1 and DLEU tumor suppressor genes displayed
diminished expression associated with loss. In another study,
recurrent deletion of tumor suppressor genes BCL7A, SMAC/
DIABLO, and RHOF in MF was observed.4 Genomic patterns
characteristic of MF differ markedly from SS.5 This might impli-
cate discriminative molecular pathogenesis and different therapeu-
tic requirements.
The RAS-RAF-MEK-ERK signaling pathway regulates cell
responses to environmental stimuli and plays a crucial role in many
cancers.6 Thus, RAF and MEK are attractive therapeutic targets.7,8
RAS is a small guanine-nucleotide binding protein that is attached
to the inner side of the plasma membrane. Activation of RAS
causes RAF recruitment and activation by phosphorylation. Acti-
vated RAF kinase phosphorylates and activates MEK, which
phosphorylates ERK. Three RAS (KRAS, NRAS, and HRAS),
3 RAF (ARAF, BRAF, and CRAF), 2 MEK (MEK1 and MEK2),
and 2 ERK (ERK1 and ERK2) isoforms compose the “canonical”
mitogen-activated protein kinase pathway. Somatic mutations that
are found in many cancers, including colon carcinoma, melanoma,
or pancreatic cancer, occur almost exclusively in BRAF, KRAS, or
NRAS isoforms.9-11 Typical mutations affect glycine 12 (G12),
glycine 13 (G13), or glutamine 61 (Q61) and keep RAS in an
activated form. The RAS pathway regulates survival, proliferation,
senescence, and differentiation. However, in tumor cells, mutated
(oncogenic) RAS preferentially promotes survival and prolifera-
tion. Thus, RAF and MEK kinases serve as suitable drug targets.
RAF is targeted by inhibitors in preclinical or clinical development,
including, for example, RAF265 and PLX4720.12,13 However,
targeting the RAF pathway is complex because of the modes of
pathway activation and regulation. Recently, it was shown that
RAF265 and PLX4720 block MEK-ERK signaling and tumor
growth only in cancers harboring a BRAFV600E mutation but not in
wild-type BRAF or tumors with a KRAS mutation.12,14,15 Further,
treating wild-type BRAF tumors with BRAFV600E specific inhibi-
tors induced tumor growth in vitro and in vivo.14 Thus, MEK
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inhibitors might be of interest in wild-type BRAF cells. Presently,
these inhibitors are in dose-finding and early phase 2 studies.8,16,17
AZD6244, a non–adenosine triphosphate-competitive specific MEK
inhibitor, was evaluated in a phase 1 clinical trial and reached an
appropriate safety profile for further studies.16 It interferes with
epidermal homeostasis.18 In a phase 2 clinical trial, AZD6244
showed similar efficacy with respect to progression-free survival as
control treatment.19 In a phase 2 clinical trial of 200 patients with
melanoma patients, AZD6244 monotherapy resulted in lasting
remissions, mainly in patients with documented BRAF muta-
tions.20 Another specific inhibitor targeting MEK is PD0325901.
PD0325901 treatment was shown to affect retinal function in
clinical trials. Therefore, its development was discontinued.8
No extensive search for point mutations in CTCL has been
reported so far. In the present study, we analyzed CTCL samples by
a mass-spectrometric genotyping approach, termed OncoMap.21,22
This analysis revealed oncogenic mutations in RAS kinase in 4 of
90 CTCL patients and in 4 of 42 of late disease CTCL patients. In
addition, we identified an oncogenic NRASQ61K mutation in the
CTCL cell line Hut78 that results in hyperactivation of the RAS
pathway. We show that this oncogenic mutation creates an “addic-
tion” to the RAS-RAF-MEK signaling pathway and sensitizes
toward treatment with the specific MEK inhibitors AZD6244,
PD0325901, and U0126.
Methods
Patient samples
Ninety CTCL samples were collected at the Department of Dermatology,
University Hospital of Zurich (n  78) and at the Department of Dermatol-
ogy, Yale School of Medicine (n  12). The study group included
40 females and 50 males (mean age, 66.4 years; minimum, 19.4 years;
maximum, 95.6 years) and consisted of 41 MF, 36 SS, and 13 non-MF/SS
CTCL patients (7 anaplastic large cell CD30 CTCLs, 5 CD4 small/
medium pleomorphic CTCLs, and 1 peripheral aggressive CD8 CTCL).
Staging at diagnosis was as follows: 40 stage I, 4 stage II, 4 stage III, and
42 stage IV.23 Complete lifetime data (first diagnosis, last visit, or date of
death) for survival function (ie, Kaplan-Meier curve) was available from
68 patients. Samples consisted of 44 skin (cryo-asserved tissue samples)
and 46 blood (peripheral blood mononuclear cells) samples. The clinical
presentation of each individual CTCL patient defined the source (skin or
blood) of each sample. In general, cryo-asserved tissue samples were
collected at early stages when the skin affection was predominant, and
peripheral blood mononuclear cells were gathered at later stage CTCL when
blood involvement was anticipated. DNA was extracted from all samples
for diagnostic purposes and analyzed with a polymerase chain reaction
(PCR)–based clonality assay (PCR-denaturing gradient gel electrophoresis).
Clonality was present within the T-cell receptor- locus in all samples.24
All patients gave informed consent in accordance with the Declaration
of Helsinki. The local ethical boards approved the study (Massachusetts
Institute of Technology COUHES protocol #0806002814). Details of the
patient samples with mutations are shown in Table 1.
OncoMap 3 Core mass-spectrometric genotyping
Briefly, samples were run through OncoMap 3, which addresses
396 somatic mutations across 33 genes (supplemental Table 1, available on
the Blood Web site; see the Supplemental Materials link at the top of the
online article). Whole genome amplified DNA at 5 ng/L was used as input
for multiplex PCR as described previously.21,22 Products were resigned and
transferred to SpectroCHIPs for analysis by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry. Allele peaks were analyzed
manually (supplemental Figure 1); candidate mutations were validated
using multibase hME extension chemistry as previously described.21,22
Primers and probes were designed using Sequenom MassARRAY Assay
Design, Version 3.0 software, applying default multibase extension parame-
ters but with the following modifications: maximum multiplex level input
adjusted to 6; maximum pass iteration base adjusted to 200.
Illumina sequencing
PCR was performed on 90 formalin-fixed, paraffin-embedded samples
using primers for KRAS codon 61, NRAS codons 12/13, and NRAS codon
61 amplification. Reverse primers were tagged at the 5 end with a 6-bp
barcode (primer sequences indicated in supplemental Table 2). To amplify
KRAS codons 12/13, a nested PCR was performed; 1 L of a 1:10 dilution
was used as input for a second round of PCR. DNA gel electrophoresis was
used to confirm the presence of 60-bp DNA products. Illumina sequencing
was performed by the Harvard Biopolymers Facility, Harvard Medical
School. The output consisted of approximately 30 million 40-bp fragments
per lane; these were aligned to genomic chromosome (HG18) reference
sequences using NovoAlign (Novocraft Technologies); alignment coordi-
nates and mismatch positions for aligned fragments were provided by the
Harvard Biopolymers Facility. Approximately 15 million reads yielded
useful alignment information. Reads with insufficient quality at any base or
with truncated barcode regions were excluded from analysis. Approxi-
mately 13 million fragments were deemed high quality.
Each high-quality fragment was assigned to its corresponding tumor
sample using the identity of bases in the barcode region. The presence of
mutation at the bases of interest in KRAS codons 12/13, KRAS codon
61, NRAS codons 12/13, and NRAS codon 61 was also noted, and average
variant frequency and quality for each allele at the target base were
calculated. A 5% background “noise” rate was assumed; variants with
insufficient reads to rise above this baseline frequency were excluded from
analysis.
Table 1. RAS mutations in CTCL patients: characteristics of patients with mutations
Characteristic Patient 1 Patient 2 Patient 3 Patient 4
Diagnosis CTCL, pleomorphic Sézary syndrome Mycosis fungoides CTCL, CD30
Mutation KRAS (G13D) NRAS (Q61K) KRAS (G13D) NRAS (Q61K)
Sex Male Female Male Male
Age, y 70 75 45 61
TNMB stages T3 N3 M0 B0 T4 N3 M0 B1 T3 N3 M1 B0 T3 N3 M0 B0
Staging IVA2 IVA2 IVB IVA2
Tissue CATS PBMCs CATS CATS
Skin Disseminated papules and
small tumors
Melano erythroderma without palmoplantar
hyperkeratosis
Disseminated tumors with a size up to
5 cm diameter
Right shoulder singular
4  3-cm firm tumor
Lymphocytes,  103 L 1.1 1.48 3.6 2.1
Sézary cells,% None 20%-30% None None
CD4/CD8 ratio 4.3 6 16.7 1.3
CATS indicates cryo-asserved tissue samples; and PBMCs, peripheral blood mononuclear cells.
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Chemicals
U0126 was purchased from Sigma-Aldrich. AZD6244 and PD0325901
were provided by Dr C. Falk (Heidelberg). All inhibitors were solubilized in
dimethyl sulfoxide at stock concentrations of 5mM.
Cell culture
CTCL cell lines SeAx, Hut78, MyLa, and HH cells were cultured in RPMI
medium supplemented with 10% fetal calf serum and 1mM L-glutamine.
Western blot analysis
A total of 1  106 CTCL cells were lysed for 10 minutes in ice-cold
radioimmunoprecipitation assay lysis buffer (50mM Tris-HCl, pH 8.0,
120mM NaCl, 1% NP-40, 0.5% Na-desoxycholate, 0.1% sodium dodecyl
sulfate, 2mM ethylenediaminetetraacetic acid, 25mM NaF, 0.2mM NaVO4,
1mM dithiothreitol, and complete protease inhibitor cocktail from Roche
Diagnostics). Cell debris was removed by centrifugation at 17 000g for
30 minutes, and equal amounts of protein were separated by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis. Then, separated pro-
teins were blotted onto a nitrocellulose membrane (GE Healthcare)
followed by blocking with 5% bovine serum albumin in phosphate-buffered
saline/Tween (0.05% Tween-20 in phosphate-buffered saline). The follow-
ing antibodies were used: anti-phospho-ERK (P-p44/p42 (Tyr202/204; Cell
Signaling Technology), anti-ERK2 (C-14; Santa Cruz Biotechnology),
anti-phospho-MEK1/2 (Ser217/212; Cell Signaling Technology), anti-
MEK1/2 (rabbit; Cell Signaling Technology), anti-NRAS (F155; Santa
Cruz Biotechnology), and anti–tubulin (Sigma-Aldrich).
PCR and sequencing of cell lines
Total cellular RNA was isolated using the Absolutely mRNA Purification
Kit (Stratagene). Total RNA (5 g) was reverse transcribed with a reverse
transcription-PCR kit (Applied Biosystems); 5 L of cDNA was used for a
PCR of 50 L volume. The following primers were used: KRAS forward,
5-aggcctgctgaaaatgactg-3; KRAS reverse, 5-ccaaaaaccccaagacagaa-3;
NRAS forward, 5-ggggtctccaacatttttcc-3; NRAS reverse, 5-cccagggca-
gaaaaataaca-3; HRAS forward, 5-ggggcaggagaccctgtag-3; HRAS re-
verse, 5-tttttcaagaccatccaataattt-3; BRAF_exon15 forward, 5-tcataatgctt-
gctctgatagga-3; BRAF_exon15 reverse, 5-ggccaaaatttaatcagtgga-3. PCR
was performed, and 30 L of PCR product was sent for sequencing to
Genetic Analysis Technology Consortium. For sequencing, the same
primers were used as for PCR.
siRNA transfection and knockdown. SeAx, Hut78, MyLa, and HH
cells were transfected by Amaxa transfection kits (Lonza Walkersville) with
Allstars Negative Control siRNA (QIAGEN) or siRNA oligonucleotides
specific for NRAS: siNRAS1 5-GCGCACUGACAAUCCAGC-
UAAUCCA-3; siNRAS2 5-GGACAUACUGGAUACAGCUGGACAA-
3. SeAx and MyLa cells were transfected with Amaxa transfection kit V
according to the protocol established for Jurkat cell lines. Hut78 and HH
cells were transfected with Amaxa transfection Kit R (Lonza) according to
the protocol established for the Hut78 cell line.
Cell death assays. For cell death induction, CTCL cells were
stimulated with the indicated concentrations of inhibitors. Cell death was
assessed by forward-to-side-scatter profile.25 Specific cell death was
calculated using the following equation: specific cell death %  [(%
experimental cell death  % spontaneous cell death)/(100%  % spontane-
ous cell death)]  100.
Results
High-throughput mutation profiling and next-generation
sequencing of CTCL samples reveals KRAS and NRAS
mutations in advanced disease
We identified mutations in KRAS (G13D) and NRAS (Q61K) in
4 of 90 patients: one MF, one SS, one CD30 CTCL, and one
pleomorphic CTCL with lymph node involvement (Table 1).
Interestingly, all patients harboring KRAS/NRAS mutations were
stage IV (Table 1), whereas none of the earlier stage patient
samples demonstrated point mutations (P  .04, Fisher exact test).
Illumina sequencing of the same 90 samples showed the identical
samples being mutated without revealing any additional mutated
samples (supplemental Table 2). Illumina mutant allele frequency
ranged from 10.69% to 56.24%. These results show that CTCL
patients harbor mutations within the RAS pathway and that these
mutations are found at a later stage of the disease.
Patients harboring samples with KRAS/NRAS mutations
display a significantly reduced survival
Stage IV patients with RAS mutations showed a significantly
reduced survival compared with stage IV patients without muta-
tions (P  .04; Figure 1). Comparing stage IV patients with
mutated samples to all patients without mutation (ie, stage IV
patients without mutated samples plus stage I-III patients; ie,
non–stage-corrected) revealed an even increased significance
(P  .02; Figure 1). Taken together, we conclude that mutations
within the RAS pathway in CTCL patients are associated with an
unfavorable clinical outcome.
Direct DNA sequencing reveals NRAS mutation in the CTCL cell
line Hut78
We further investigated the implications of RAS mutations on
survival and signaling in CTCL. Therefore, we specifically screened
for mutations in KRAS, NRAS, HRAS, and BRAF in the 4 CTCL
cell lines SeAx, Hut78, MyLa, and HH. By direct DNA and cDNA
sequencing, we found a homozygous thymidine-to-cytosine conver-
sion at position 270 of HRAS in the SeAx cell line that resulted in a
silent mutation at codon 25. More importantly, we discovered a
heterozygous cytosine-to-adenosine conversion at position 436 in
the Hut78 cell line. This conversion generates a glutamate-to-lysine
exchange at codon 61 (Q61K) (Figure 2A). We did not detect other
mutations in KRAS, HRAS, NRAS, or BRAF at critical sites,
including codon 12, 13, and 61 for RAS or codon 600 for BRAF,
respectively9-11 (Figure 2B). RAS kinases are best known as key
regulators of the MEK-ERK cascade. Oncogenic NRASQ61K muta-
tions result in hyperactive RAS, which activates the downstream
MEK-ERK signaling cascade,26 thus mediating a prosurvival
signal. To analyze for differential activation of the MEK-ERK
cascade, we assayed the phosphorylation status of MEK and ERK
in all 4 cell lines. Indeed, we observed that ERK phosphorylation
Figure 1. CTCL stage IV patients harboring a RAS mutation show reduced life
expectancy. Kaplan-Meier curve: Comparison of survival of mutant (all stage IV),
nonmutant stage IV patients (P  .041), and nonmutant stage I to III patients
(P  .001). P values were determined by Student t test (2-tailed) comparing
individual group versus the mutant patient samples group. Similarly, the 2 nonmutant
groups, when considered together, showed significance for prolonged survival
compared with the mutant patient samples group (P  .017, 2-tailed Student t test).
Considered are time span from first diagnosis to date of death or last visit, when
applicable, respectively.
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was most prominent in the HUT78 cell line, whereas ERK
phosphorylation was less pronounced in SeAx, Myla, or HH cells
(Figure 2C). Of note, nonphosphorylated basal ERK expression
was comparable in all 4 cell lines (Figure 2C). Although nonphos-
phorylated basal MEK expression differed in all cell lines, the
highest MEK phosphorylation was detected in Hut78 cells carrying
the oncogenic NRASQ61K mutation (Figure 2D). Thus, our data
show an activating NRASQ61K mutation in the CTCL cell line
Hut78 inducing the MEK-ERK signaling cascade.
Oncogenic NRASQ61K is critical for survival of Hut78 cells
To investigate the role of oncogenic NRASQ61K for survival of
Hut78 cells, we performed a specific NRAS knockdown by
2 different siRNAs. Delivery of specific siRNAs against NRAS
resulted in a substantial decrease of NRAS expression compared
with a non-sense control siRNA (Figure 3A). Importantly, the
efficiency of NRAS knockdown was comparable in all 4 cell lines
(Figure 3A). Knockdown of NRAS strongly diminished phosphor-
ylation of MEK and ERK in Hut78 but not in SeAx cells (Figure
3A). This demonstrates that MEK and ERK activation is dependent
on NRAS in Hut78 but not in SeAx cells. Moreover, knockdown of
NRAS resulted in induction of cell death exclusively in the
NRASQ61K carrying Hut78 cell line but not in the cell lines SeAx,
MyLa, and HH without oncogenic NRAS (Figure 3B). These
results show that Hut78 is addicted to oncogenic NRASQ61K and
that the hyperactived RAS pathway is required for survival.
MEK inhibitors cause growth inhibition in Hut78 cells
RAS mutations occur in approximately 4 of 36 CTCL patients at
advanced disease stage IV. RAS mutations were associated with
poor prognosis compared with nonmutant RAS patients at stage IV.
This prompted us to ask whether inhibitors of the RAS/RAF/MEK/
ERK pathway could be of relevance for treatment of RAS mutated
patients. Because RAS and RAF mutations are found in nearly 30%
of human cancers, several MEK inhibitors are under clinical
development.26 AZD6244 and PD0325901 were both shown to be
potent MEK inhibitors that inhibit cell growth in vitro and in
vivo.27,28 Both inhibitors recently entered phase 2 clinical trials.16,17
AZD6244, PD0325901, and the MEK inhibitor U0126 blocked
basal ERK phosphorylation in Hut78 cells (Figure 4A). This
suggests that MEK inhibitors are taken up in cell lines and inhibit
RAS-RAF-MEK-ERK signaling. Phosphorylation of MEK was
slightly increased by AZD6244 and PD0325901 but not by U0126
in both cell lines (Figure 4A). In addition, we investigated the
inhibitory effect of the MEK inhibitors on cell growth. We
observed that Hut78 cells respond for significantly inhibitor
concentrations compared with SeAx, MyLa, and HH cells (Figure
4B-D). The 50% inhibitory concentration values for Hut78 were:
3.1nM for AZD6244, 68nM for PD0325901, and 39nM forU0126.
Figure 2. CTCL cell line Hut78 harbors Q61K mutation for NRAS. (A) RNA was
isolated and reverse transcribed to cDNA for all 4 cell lines. Next, PCR was performed
covering the open reading frame of KRAS, NRAS, HRAS, and BRAF. PCR products
were purified and sent for sequencing. Results were evaluated by Genetic Analysis
Technology Consortium sequence viewer. Arrow indicates cytosine-to-adenosine
conversion. (B) Table of sequencing results for all 4 CTCL cell lines. A heterozygous
Q61K mutation was detected for the Hut78 cell line. A homozygous silent H25H
mutation was found in the SeAx cell line. (C) All 4 cell lines were kept under equal
conditions, lysed, and and lysates subjected to Western blot. Phosphorylation of ERK
was assayed by anti-phospho-specific ERK antibodies. Equal expression of ERK
was verified by anti-ERK2 antibodies, and equal loading was verified by anti–tubulin
antibodies. Quantification of phosphorylated ERK to ERK2 was done with ImageJ
1.43 Quantification software. (D) Same as panel C, but anti-phospho-specific MEK
antibodies and anti-MEK antibodies were used to assess the phosphorylation status
of MEK and MEK expression, respectively. Equal loading was verified by antitubulin
antibodies.
Figure 3. NRASQ61K is required for survival of the CTCL cell line Hut78.
(A) siRNA against NRAS (siNRAS1 and siNRAS2) were transfected in SeAx, Hut78,
MyLa, and HH cell lines by the Amaxa kit and protocol. At 72 hours after transfection,
cells were lysed and lysates subjected to Western blot. Efficiency of knockdown was
measured by anti-NRAS antibodies. Levels of phosphorylation of MEK and ERK were
assessed by anti-phospho-specific MEK and anti-phospho-specific ERK in SeAx and
Hut78 cells. Equal loading was verified by antitubulin antibodies. (B) Apoptosis was
measured starting 3 days after siRNA transfection for 24, 48, and 72 hours. Specific
apoptosis was calculated as described in “Cell death assays.” Data are representa-
tive of 3 independent experiments.
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This shows that NRASQ61K sensitizes cells toward treatment with
MEK inhibitors strongly affecting cell growth.
MEK inhibitors induce apoptosis uniquely in Hut78 cells
To check whether NRASQ61K also sensitizes toward induction of
apoptosis in CTCL, we treated the CTCL cell lines with the 3 MEK
inhibitors and measured cell death after 48 and 72 hours. As
expected, AZD6244, PD0325901, and U0126 induced apoptosis up
to 90% in the NRASQ61K harboring Hut78 cell line only, whereas
cell lines without this mutation were refractory (Figure 5). Of note,
apoptosis induction occurred already at low concentrations of the
inhibitor (100nM to 500nM). These concentrations are clinically
relevant plasma concentrations (eg, for AZD6244).29 Taken
Figure 4. NRASQ61K sensitizes for treatment with
MEK inhibitors. (A) Hut78 cells were left untreated or
treated with 1M AZD6244, 1M PD0325901, and 1M
U0126 for 4 hours. Then, cells were lysed, and the basal
phosphorylation level of ERK and MEK was assessed by
Western blot with specific anti-phospho-ERK and with
specific anti-phospho-MEK antibodies. Equal loading
was verified by antitubulin antibodies. (B-D) CTCL cell
lines were incubated with indicated concentrations of
MEK inhibitors U0126 (B),AZD6244 (C), and PD0325901
(D) for 72 hours. Cell growth was measured by Cell Titer
Glo according to the manufacturer’s instructions. The
50% inhibitory concentration values, at which 50% of the
cell growth inhibition compared with dimethyl sulfoxide
was observed, were calculated by GraphPad Prism
Version 5 software. Data are representative for 3 indepen-
dent experiments.
Figure 5. NRASQ61K sensitizes for apoptosis by MEK
inhibitors. (A-C) All 4 CTCL cell lines were incubated
with indicated concentrations of MEK inhibitors U0126 (A),
AZD6244 (B), and PD0325901 (C) for 48 hours (left) and
72 hours (right). Then, apoptosis was determined, and
specific apoptosis was calculated as described in “Cell
death assays.” Data are representative at least 3 indepen-
dent experiments.
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together, these results show that NRAS mutations confer sensitivity
toward different MEK inhibitors in CTCL.
Discussion
We analyzed 90 samples of CTCL patients by OncoMap and found
2 KRAS (G13D) and 2 NRAS (Q61K) mutations. Our results were
validated by next-generation sequencing (Illumina).
Activating KRAS and NRAS mutations are among the most
common oncogenic lesions detected in human cancer, including
myeloproliferative disorders and leukemias (eg, acute lymphoblas-
tic leukemia).30 In a mutation screen of key exons of a distinct set of
genes (NRAS, KRAS, FLT3, PTPN11, and BRAF) in acute
lymphoblastic leukemia at diagnosis and disease recurrence, it was
shown that somatic mutations deregulating the mitogen-activated
protein kinase pathway were present in 35% and 25%, respec-
tively.31 Sabnis et al showed that KRAS initiates leukemia in
hematopoietic stem cells.32 Earlier, immunohistochemistry dis-
played increased detection of RAS in advanced stages of MF
compared with early stages.33 On the RNA or protein level, an
overexpression of the rab2 gene (belonging to the RAS superfam-
ily) was detectable in SS patients. These results were later
confirmed for KRAS.34 In line with these reports, it is not
surprising that CTCLs show mutations in KRAS and NRAS. We
hypothesize that RAS mutations reveal a late event in the course of
CTCL and are not mutations that induce this type of lymphoma.
We also identified a CTCL cell line that carries the same
mutation for NRAS (Q61K) as detected in patient samples. This
cell line (Hut78) was isolated from a patient with SS, a severe form
of CTCL.35 The stage of this patient was not reported in the
publication.36 The NRAS mutation correlated with stronger
MEK-ERK signaling compared with other cell lines that do not
show this mutation.
The overall survival of the patients with KRAS/NRAS muta-
tions decreased significantly compared with patients without
mutations within the same stage group. This observation is
interesting compared with findings in other tumors. The RASCAL
II study analyzed the impact of KRAS mutations on survival for
3439 colon carcinoma patients.37 KRAS mutations had no overall
effect on survival. Only one specific mutation (glycine-to-valine
conversion at codon 12) in KRAS, which occurs in approximately
9% of patients, predicted a poorer prognosis.37 The impact of RAS
mutations on survival for acute myeloid leukemia is discussed
controversially. Seven studies showed a similar clinical outcome,
3 studies showed a worse clinical outcome, and 2 studies a
favorable prognosis for patients harboring RAS mutations.38 This
suggests that RAS mutations have a very mild, or most probably no
effect on survival of acute myeloid leukemia patients. Interestingly,
acute myeloid leukemia patients carrying RAS mutations benefited
from a higher chemotherapeutic dose, indicating that oncogenic
mutations may confer higher sensitivity to certain treatments.38 It
has been reported that NRASQ61R mutations may sensitize to BRAF
inhibition or that NRASG13A mutation confers resistance toward
apoptosis.39-41 Thus, these data suggest that patients with RAS
mutations benefit from treatment inhibiting the RAS-RAF-MEK-
ERK pathway. We have observed that knockdown of NRAS by
2 different siRNAs induces apoptosis in Hut78 cells but not in cell
lines harboring WT RAS, thus suggesting that Hut78 depends on
hyperactive RAS-RAF signaling.
This dependency on RAS signaling could therefore have
therapeutic implications for these patients. Indeed, we found that
the NRAS mutation sensitizes toward treatment with MEK inhibi-
tors AZD6244, PD0325901, and U0126. All 3 inhibitors caused
apoptosis in Hut78 cells and not in the other cell lines devoid of the
respective NRAS mutation. These results suggest that CTCL
patients with RAS mutations may benefit from treatment with
MEK inhibitors.
Whether KRAS mutations also can sensitize toward MEK
inhibitors could not be studied because of the absence of this
mutation in CTCL cell lines. However, other studies have shown
that KRAS mutant cell lines are dependent on KRAS hyperactivity
for cell growth and survival.42
Survival of mutant RAS CTCL patients was significantly
different from wild-type RAS CTCL patients within the same
stage. However, RAS mutations display a rare event, and other
genetic or epigenetic alterations should be considered. Evidence of
epigenetic silencing of several individual genes by methylation
(besides p16) has previously been reported: p15 (CDKN2B),43
MLH1, thrombospondin 4 (THBS4), BCL7A, and PTPRG.44 Mao
et al found heterogeneous abnormalities of CCND1 and RB1 in
CTCL, suggesting impaired cell cycle control in disease pathogen-
esis.45 In a further study, some patients showed a deletion or
translocation affecting NAV3.46 Using CGH, loss of heterozygosity
has been described for phosphatase and tensin homolog,47 and
amplified chromosomal regions for HER-2/neu (ERBB2) have
been reported.48 Recently, microarray studies, performed to iden-
tify gene expression patterns in CTCL, highlighted the tumor
necrosis factor signaling pathway, Th2-specific transcription fac-
tors (eg, JUN-B, GATA-3),49 MYC, and TP53, among others.
CTCL might represent a malignancy in which epigenetic change
rather than mutations are pivotal. The latter is consistent with the
observation that CTCL therapies interfering with transcriptional
regulation (eg, interferon, retinoids, and histone deacetylase inhibi-
tors) show hitherto a promising outcome. Nevertheless, certain
patient subgroups may benefit from target tumor therapy, as this
study shows.
Recently, the combination of molecular cytogenetics (CGH)
and microarray gene expression analysis has shown chromosomal
arms where DNA and the corresponding RNA copy numbers are
altered, including 1q, 3p, 3q, 4q, 12q, 16p, and 16q. These regions
probably harbor further gene-level aberrations in CTCL.50 In the
near future, the use of next-generation sequencing focusing on
these chromosome arms could reveal novel pivotal genes in the
pathogenesis, diagnostic classification, and therapy of CTCL.
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